

ADHERIZE+ PLATFORM UPDATE

Thetford Mines, Quebec – March 21, 2024 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”) is pleased to announce an update in the development and use of its Adherize+ platform. With the aim of assisting and improving the follow-up of hormone-dependent breast cancer patients taking oral CDK 4/6 inhibitor therapy, the Corporation, through its Adherize+ platform, will develop the monitoring and follow-up algorithm for these patients in collaboration with oncology physicians and pharmacists.

CDK 4/6 inhibitors are proven effective treatments for many hormone-dependent breast cancers in the adjuvant (preventive) or metastatic (palliative) setting, in combination with an aromatase inhibitor. Adherize+ will be able to maximize real-time treatment management between healthcare providers and patients receiving this drug, enabling direct and active communication in monitoring adherence and any adverse effects that may occur during the prescribed course of treatment.

This new relationship created by Adherize+ will bring peace of mind to every patient, who will be able to access rapid communication and a wealth of information to reassure and support them in following and respecting their treatment according to recognized medical and therapeutic recommendations, for example automatic dosage adjustments based on laboratory tests performed.

Canadian and Quebec epidemiological data

It is estimated that in 2023, 239,100 Canadians will be diagnosed with cancer, and 86,700 will die from it. Lung and bronchial cancer, breast cancer, prostate cancer and colorectal cancer are expected to account for 46% of new cancer diagnoses. Breast cancer accounts for 25.6% of newly diagnosed cancers among women.¹

In 2023, the Canadian Cancer Society estimated that 7,065 new cases of breast cancer would be diagnosed in Quebec (29,700 in Canada), and that 1,415 deaths would be recorded (5,500 in Canada). The majority of breast cancers are hormone dependent. Breast cancer is the most frequently diagnosed malignant tumor in women, and the second leading cause of cancer-related death in Quebec and Canada. Canadian women are more likely to develop breast cancer than any other cancer: it is estimated that one in 8 women will be diagnosed with breast cancer in her lifetime.¹

Adherize+ therefore becomes a simple and logical solution for any healthcare professional to ensure real-time monitoring of all their patients.

“Many new anti-cancer molecules are now administered orally, requiring rigorous outpatient monitoring. The oral route does not rule out potentially serious side effects. The number of patients to be treated is constantly increasing. In a context of manpower shortage and increasing complexity of oncology treatments, we need to be innovative and find technological solutions to treat our patients efficiently and safely. The planned development of Adherize+ should enable us to achieve these objectives, in the best interests of our patients,” said Dr. Éric Poirier, Oncology Surgeon, practicing in the Clinique des Maladies du Sein at the Centre Hospitalier Universitaire de Québec (CHU de Québec-Université Laval). Dr. Poirier is a shareholder of the Corporation.

ABOUT KDA GROUP

KDA Group is a leader in technological innovations and specialized software solutions (SAAS – Software as a Service) for the healthcare professionals’ market. KDA is a corporation that offers quality products and has a respected expertise among the various stakeholders in the pharmaceutical and medical sectors. The technology products developed by KDA aim, among other things, to accelerate the healthcare’s digital transformation, and are available for the Canadian and international markets. Additional information about the Corporation is available at www.kdagroup.com and on SEDAR+ at www.sedarplus.ca.

- 30 -

REFERENCE

1- Canadian Cancer Statistics Advisory Committee 2023, in collaboration with the Canadian Cancer Society, Statistics Canada and the Public Health Agency of Canada.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release from KDA Group contains forward-looking statements. Forward-looking statements are typically identified by the words assumption, goal, guidance, objective, outlook, strategy, target, and other similar expressions, or future or conditional verbs such as aim, anticipate, believe, predict, could, expect, intend, may, plan, seek, should, strive, and will. By their nature, forward-looking statements require us to make estimates and assumptions and express opinions based on current conditions and anticipated developments, as well as other factors that Management may deem appropriate under the circumstances. There is inherent uncertainty and significant risk in these estimates, assumptions, and opinions, particularly of a commercial, economic, and competitive nature, and they are therefore subject to change. KDA Group cannot guarantee that these estimates, assumptions, and opinions will prove to be accurate.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

INFORMATION

Marc Lemieux, Chief Executive Officer
514 622-7370
info@groupekda.ca